Premium
Pharmacokinetics of vitacoxib in rabbits after intravenous and oral administration
Author(s) -
Wang Jianzhong,
Xue Jiao,
Zhang Lu,
Zhang Suxia,
Li Jing,
Cao Xingyuan
Publication year - 2019
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12745
Subject(s) - pharmacokinetics , bioavailability , cmax , oral administration , medicine , pharmacology , pharmacodynamics , plasma concentration , drug administration , adverse effect
This study describes the pharmacokinetics of vitacoxib in healthy rabbits following administration of 10 mg/kg intravenous (i.v.) and 10 mg/kg oral. Twelve New Zealand white rabbits were randomly allocated to two equally sized treatment groups. Blood samples were collected at predetermined times from 0 to 36 hr after treatment. Plasma drug concentrations were determined using UPLC ‐ MS / MS . Pharmacokinetic analysis was completed using noncompartmental methods via WinNonlin ™ 6.4 software. The mean concentration area under curve ( AUC last ) for vitacoxib was determined to be 11.0 ± 4.37 μg hr/ ml for i.v. administration and 2.82 ± 0.98 μg hr/ml for oral administration. The elimination half‐life ( T 1/2λ z ) was 6.30 ± 2.44 and 6.30 ± 1.19 hr for the i.v. and oral route, respectively. The C max (maximum plasma concentration) and T max (time to reach the observed maximum (peak) concentration at steady‐state) following oral application were 189 ± 83.1 ng/ml and 6.58 ± 3.41 hr, respectively. Mean residence time ( MRT last ) following i.v. injection was 6.91 ± 3.22 and 11.7 ± 2.12 hr after oral administration. The mean bioavailability of oral administration was calculated to be 25.6%. No adverse effects were observed in any rabbit. Further studies characterizing the pharmacodynamics of vitacoxib are required to develop a formulation of vitacoxib for rabbits.